British dietetic association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update)
Berberine is best thought of as light support for metabolic health, not a weight-loss drug in a capsule
Eli Lilly and Company is the pharmaceutical company that makes two tirzepatide products that are approved by the Food and Drug Administration (FDA): Mounjaro, which is approved by the FDA for improving blood sugar levels in people with Type 2 diabetes, and is often prescribed off-label for weight loss Zepbound, which is FDA approved for weight loss, as well as for obstructive sleep apnea in adults with obesity Currently, there are no FDA-approved generic versions of the drugs Mounjaro or Zepbound, and there are not any other FDA-approved tirzepatide products available besides brand-name Mounjaro and Zepbound
[41] Relative contraindications may require careful risk-benefit assessment and could include conditions that might be exacerbated by corticosteroid therapy
Understanding the relationship between Zepbound and thirst helps patients maintain proper hydration and recognize when medical attention is needed
Mounjaro is only for adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) who also have weight-related health conditions such as diabetes, high blood pressure, heart disease, or high cholesterol
